Why CARMAT SAS's Artificial Heart Could Be A Big Deal

The second patient implanted with a Carmat artificial heart has gone home, opening the way for others enrolled in the French company’s clinical trial to receive the devices. Carmat designed its self-regulated, bioprosthetic heart as a permanent implant for patients with end-stage heart failure. The first trial participant who received the heart died 75 days later, likely due to a short circuit in the device. The second patient, 68, went home Jan. 2, five months after the operation at the University of Nantes hospital, according to a reportin the French newspaper Le Parisien.

Hey, check out all the engineering jobs. Post your resume today!

Back to news